A Smoking Cessation Treatment for Adult Women

Conditions

Nicotine Dependence

Trial Phase

Phase 1

Trial Purpose and Description

Trial Purpose

The purpose of this study is to develop and pilot test a smoking cessation counseling that focuses on the perceived risks of quitting smoking (e.g., weight gain, managing cravings and negative affect, loss of enjoyment).

Aim 1: To develop the risk-based smoking cessation intervention.

Aim 2: To examine whether manualized smoking cessation counseling about the perceived risks of quitting is feasible to administer and acceptable to adult women who want to quit smoking.

Aim 3: To examine smoking cessation outcomes for women who receive the risk-based treatment in comparison to standard smoking counseling. It is expected that women who receive risk-based counseling will show better quit rates and a longer time to relapse than women who receive standard treatment.


Trial Description

The purpose of this treatment development study is to design and pilot test a smoking cessation intervention in which counseling sessions are tailored to individual smokers' perceived risks of quitting. The feasibility, acceptability, and efficacy of the novel treatment will be examined through a pilot study in which female smokers will be randomly assigned to receive either the tailored treatment or a standard treatment. It is expected that participants receiving the tailored treatment will show higher rates of smoking abstinence than participants receiving the standard smoking cessation treatment at the end of the 8-week treatment and at one month follow-up.


Participation Guidelines

Age:
18 Years - 64 Years
Gender:
Female

Eligibility Criteria


Inclusion Criteria:

- Between the ages of 18 and 64 years old

- Meet Diagnostic and Statistical Manual-IV (DSM-IV) criteria for nicotine dependence
with Fagerström Test for Nicotine Dependence (FTND) score =4

- Smoke at least 15 cigarettes (3/4 pack) daily (averaged over 1 week, in the past 1
month) and have an expired breath carbon monoxide (CO) level =10

- At the time of initial evaluation, are motivated to quit smoking in the next 30 days.

- Have the capacity to give informed consent, and are English-speaking.

Exclusion Criteria:

- Have a positive urine drug screen or urine pregnancy test at baseline evaluation

- Meet DSM-IV criteria for alcohol or other drug abuse or dependence in the previous 6
months

- Meet DSM-IV criteria for a current diagnosis of major depressive disorder, panic
disorder or post-traumatic stress disorder

- Meet DSM-IV criteria for a current or past diagnosis of bipolar disorder or
schizophrenia

- Are currently receiving treatment for nicotine dependence (e.g., nicotine replacement
therapy, bupropion, chantix)
Sponsor:
National Institutes of Health (NIH)
Yale University
Dates:
January 2011
Last Updated:
June 6, 2013
Study HIC#:
1007007059

Clinicaltrials.gov ID: NCT01422239